X
[{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cartesian Therapeutics Initiates Clinical Trial of First RNA-Engineered Cell Therapy for Acute Respiratory Distress Syndrome and COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cartesian Therapeutics Wins Fourth NIH Grant for Clinical Trials of RNA Cell Therapies","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Selecta Biosciences Announces Merger with Cartesian Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cartesian Therapeutics Receives RMAT Designation for Descartes-08 in Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cartesian Therapeutics Doses First Patient in Phase 2 Trial of Descartes-08 for Lupus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cartesian Reports Positive Phase 2b Results for Descartes-08 in Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Cartesian Therapeutics
Filters
Companies By Therapeutic Area
Details:
The Company intends to use the net proceeds from the financing to fund its pipeline, which includes Descartes-08, a potential first-in-class mRNA CAR-T for patients with generalized myasthenia gravis.
Lead Product(s):
Descartes-08
Therapeutic Area: Immunology
Product Name: Descartes-08
Highest Development Status: Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Leerink Partners
Deal Size: $130.0 million
Upfront Cash: Undisclosed
Deal Type: Private Placement
July 02, 2024
Details:
Descartes-08, lead mRNA cell therapy candidate and a potential first-in-class mRNA CAR-T product candidate targeting B-cell maturation antigen (BCMA). It is under investigation for SLE.
Lead Product(s):
Descartes-08
Therapeutic Area: Immunology
Product Name: Descartes-08
Highest Development Status: Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 02, 2024
Details:
Descartes-08, lead mRNA cell therapy candidate and a potential first-in-class mRNA CAR-T product candidate targeting B-cell maturation antigen (BCMA). It is under investigation for Myasthenia Gravis.
Lead Product(s):
Descartes-08
Therapeutic Area: Immunology
Product Name: Descartes-08
Highest Development Status: Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 02, 2024
Details:
Descartes-08, the Company’s lead product candidate, is an autologous mRNA CAR-T directed against the B cell maturation antigen initially being developed for the treatment of MG.
Lead Product(s):
Descartes-08
Therapeutic Area: Immunology
Product Name: Descartes-08
Highest Development Status: Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 22, 2024
Details:
Descartes-08 is a potential first-in-class mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T). It is under phase 2 clinical development for the treatment of generalized myasthenia gravis.
Lead Product(s):
Descartes-08
Therapeutic Area: Immunology
Product Name: Descartes-08
Highest Development Status: Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 08, 2024
Details:
The net proceeds will support the development of the Cartesian pipeline through the Phase 3 study of lead product candidate, Descartes-08, a potential first-in-class RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) for the treatment of myasthenia gravis.
Lead Product(s):
Descartes-08
Therapeutic Area: Immunology
Product Name: Descartes-08
Highest Development Status: Phase II
Product Type: Cell and Gene therapy
Recipient:
Selecta Biosciences
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Merger
November 13, 2023
Details:
This $2 million competitive R&D award from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) will support Cartesian's clinical development for Descartes-30, the first RNA cell therapy for respiratory diseases.
Lead Product(s):
RNA Engineered Allogeneic Human Mesenchymal Stem Cells
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: Descartes-30
Highest Development Status: Phase I/ Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
National Institutes of Health
Deal Size: $2.0 million
Upfront Cash: Undisclosed
Deal Type: Funding
May 04, 2021
Details:
Descartes-11 is engineered with Cartesian’s RNA Armory℠ platform to express its CAR molecules transiently instead of permanently, thereby reducing both short-term and long-term risks inherent with conventional CAR T-cell therapies.
Lead Product(s):
Descartes-11
Therapeutic Area: Oncology
Product Name: Descartes-11
Highest Development Status: Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 22, 2021
Details:
The Phase 1/2 clinical trial is the first-in-human study which aims to determine the safety and preliminary efficacy of Descartes-30 in patients with moderate to severe ARDS.
Lead Product(s):
Descartes 30
Therapeutic Area: Infections and Infectious Diseases
Product Name: Descartes 30
Highest Development Status: Phase I/ Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 01, 2020